2010
DOI: 10.1186/1471-2407-10-438
View full text
|
|
Share

Abstract: BackgroundImatinib mesylate has been used for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST). The current recommended dose of imatinib is 400 mg/day that is increased to 800 mg/day in cases with disease progression. However, imatinib can be associated with diverse adverse events, which has limited its use. We report a case of severe adverse skin reactions with neutropenic fever during imatinib treatment in a patient with GIST.Case presentationA 71-year-old man was admitted w…

Expand abstract

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

1
2
0
4

Publication Types

Select...

Relationship

0
0

Authors

Journals